Abstract
GLP-1 is secreted from the small intestine in response to ingestion of nutrients. It has a powerful insulinotropic effect and stimulates beta-cell growth and is therefore being developed for treatment of type 2 diabetes. The GLP-1 analogue, exenatide, is on the market in the USA as an add-on therapy. Another strategy to increase circulating GLP-1 is to inhibit the enzyme DPP-IV which degrades endogenous GLP-1. GLP-1-based therapy results in HbA1c reductions of approximately 1 percent point, and the lack of serious side effects and the low risk of hypoglycaemic episodes are unique traits.
| Translated title of the contribution | [GLP-1-based treatment of type 2 diabetes mellitus] |
|---|---|
| Original language | Danish |
| Journal | Ugeskrift for Laeger |
| Volume | 169 |
| Issue number | 22 |
| Pages (from-to) | 2095-9 |
| Number of pages | 5 |
| ISSN | 0041-5782 |
| Publication status | Published - 28 May 2007 |
